Kush Dalal - Search Results

Year	Number of Results
2005	1
2006	1
2007	1
2008	1
2009	2
2010	2
2011	1
2012	2
2013	3
2014	2
2015	2
2016	1
2017	7
2018	6
2020	1
2021	0

1

Androgen receptor-binding sites are highly mutated in prostate cancer.

Morova T, McNeill DR, Lallous N, Gönen M, Dalal K, Wilson DM 3rd, Gürsoy A, Keskin Ö, Lack NA. Morova T, et al. Among authors: dalal k. Nat Commun. 2020 Feb 11;11(1):832. doi: 10.1038/s41467-020-14644-y. Nat Commun. 2020. PMID: 32047165 Free PMC article.

2

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME. Borgmann H, et al. Among authors: dalal k. Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26. Eur Urol. 2018. PMID: 28851578

3

Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer.

Ban F, Dalal K, LeBlanc E, Morin H, Rennie PS, Cherkasov A. Ban F, et al. Among authors: dalal k. Mol Inform. 2018 Sep;37(9-10):e1800043. doi: 10.1002/minf.201800043. Epub 2018 May 7. Mol Inform. 2018. PMID: 29733509 Review.

4

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules.

Lee CCW, Munuganti RSN, Peacock JW, Dalal K, Jiao IZF, Shepherd A, Liu L, Tam KJ, Sedgwick CG, Bhasin S, Lee KCK, Gooding L, Vanderkruk B, Tombe T, Gong Y, Gleave ME, Cherkasov A, Ong CJ. Lee CCW, et al. Among authors: dalal k. J Endocr Soc. 2018 Oct 11;2(12):1381-1394. doi: 10.1210/js.2018-00170. eCollection 2018 Dec 1. J Endocr Soc. 2018. PMID: 30534631 Free PMC article.

5

The SecY complex: conducting the orchestra of protein translocation.

Dalal K, Duong F. Dalal K, et al. Trends Cell Biol. 2011 Sep;21(9):506-14. doi: 10.1016/j.tcb.2011.04.005. Epub 2011 May 31. Trends Cell Biol. 2011. PMID: 21632250 Review.

6

Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.

Lallous N, Dalal K, Cherkasov A, Rennie PS. Lallous N, et al. Among authors: dalal k. Int J Mol Sci. 2013 Jun 14;14(6):12496-519. doi: 10.3390/ijms140612496. Int J Mol Sci. 2013. PMID: 23771019 Free PMC article. Review.

7

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.

Dalal K, Munuganti R, Morin H, Lallous N, Rennie PS, Cherkasov A. Dalal K, et al. Methods Mol Biol. 2016;1443:31-54. doi: 10.1007/978-1-4939-3724-0_4. Methods Mol Biol. 2016. PMID: 27246333

8

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.

Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS. Singh K, et al. Among authors: dalal k. Int J Mol Sci. 2018 Feb 15;19(2):579. doi: 10.3390/ijms19020579. Int J Mol Sci. 2018. PMID: 29462880 Free PMC article.

9

Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.

Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Tam KJ, et al. Among authors: dalal k. Oncotarget. 2017 Feb 7;8(6):9617-9633. doi: 10.18632/oncotarget.14168. Oncotarget. 2017. PMID: 28038451 Free PMC article.

10

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, Shepherd A, Sharma A, Peacock J, Carlson ML, LeBlanc E, Perez C, Duong F, Ong CJ, Rennie PS, Cherkasov A. Dalal K, et al. Cancer Lett. 2018 Nov 28;437:35-43. doi: 10.1016/j.canlet.2018.08.016. Epub 2018 Aug 27. Cancer Lett. 2018. PMID: 30165195

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results